SIRION Receives ISO 9001:2015 Certification
Munich, Germany, February 23, 2022 – SIRION Biotech GmbH is proud to announce our achievement of...
Newsroom
PerkinElmer’s SIRION Biotech Teams with Centre for Genomic Regulation to Develop New Generation AAV Vectors for Type 1 and Type 2 Diabetes Gene Therapy
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
...
SIRION Biotech Granted CIR accreditation by French Ministry of Higher Education, Research and Innovation
Munich, October 8, 2021: The French Ministry of Higher Education, Research and Innovation have...
PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech
Solutions to complement Company’s growing position in cell and gene therapy research and development
Bavarian Technology Trio Racing Forward
Bavarian trio unite for French round-the-world sailing race: NanoTemper and SIRION Biotech support...
SIRION Biotech Announces Collaboration with Sanofi to Innovate Gene Therapy Treatments with Improved Adeno-Associated Virus Capsids
Joining forces to develop gene therapies for multiple life-threatening disorders
MUNICH, Germany,...
SIRION Biotech licenses its LentiBOOST® transduction technology to Cellectis
Munich, Germany and Cambridge, Mass., January 7, 2021– Through this license agreement, SIRION...
Subscribe Here!
Contact Us
Whether you seek help customizing a vector for academic use or support for your industrial R&D, we will assist you from square one to discuss and plan your project in detail.
News
SIRION Biotech licences its LentiBOOST® transduction technology to Cellectis
Meet us
AAV Webinar
On Demand
Swiss Biotech Day 2023
April 24-25, Basel
DG-GT Theme Day
27-28 April 2023, Langen